Navidea Biopharmaceuticals (FRA:NO1A) Interest Expense : €-0.58 Mil (TTM As of Sep. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Navidea Biopharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Navidea Biopharmaceuticals's interest expense for the three months ended in Sep. 2023 was € -0.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.58 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Navidea Biopharmaceuticals's Operating Income for the three months ended in Sep. 2023 was € -2.00 Mil. Navidea Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was € -0.10 Mil. Navidea Biopharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Navidea Biopharmaceuticals Interest Expense Historical Data

The historical data trend for Navidea Biopharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Interest Expense Chart

Navidea Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.01

-1.04

Navidea Biopharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-0.77	-0.23	-0.25	-	-0.10

Navidea Biopharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.58 Mil.

Navidea Biopharmaceuticals (FRA:NO1A) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Navidea Biopharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was €-0.10 Mil. Its Operating Income for the three months ended in Sep. 2023 was €-2.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was €0.00 Mil.

Navidea Biopharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Navidea Biopharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Navidea Biopharmaceuticals (FRA:NO1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (FRA:NO1A) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

NAVB:USA

Address

4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552

Website

https://www.navidea.com

Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.

Navidea Biopharmaceuticals (FRA:NO1A) Headlines

No Headlines